Sign in

You're signed outSign in or to get full access.

Nevin Jacob

Research Analyst at RBC Capital Markets

Nevin Jacob is a Research Analyst at RBC Capital Markets, specializing in equity research with a focus on biotechnology and healthcare sectors. He has actively engaged with companies such as Prothena Corp Public Ltd and Infigen Energy, participating in earnings calls, though specific performance metrics like success rates or rankings on platforms such as TipRanks are not publicly detailed. Jacob's career includes his current role at RBC Capital Markets, with prior mentions in earnings transcripts indicating ongoing analyst activities, but detailed timelines or previous firms remain unavailable; professional credentials such as FINRA registrations are not specified in available sources.

Nevin Jacob's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership

Question · Q4 2025

Nevin Jacob asked about the mechanistic hypotheses for how transferrin modification reduces ARIA risk, the potential for lower heme toxicities with this approach, and whether the PRX-012-TfR would still enable subcutaneous delivery.

Answer

Gene Kinney, President and CEO, discussed hypotheses for ARIA reduction, including altered penetration into cerebral vasculature and reduced dwell time on vascular amyloid due to transcytosis, confirming that subcutaneous delivery is still expected for PRX-012-TfR. Phil Dolan, VP and Head of Discovery Research, added that PRX-012's potency might allow for lower dosing, potentially minimizing non-ARIA AEs like anemia.

Ask follow-up questions

Fintool

Fintool can predict PROTHENA CORP PUBLIC LTD logo PRTA's earnings beat/miss a week before the call